2019-2020 Influenza Vaccine Codes and Pricing

2019-2020 Influenza Vaccine Codes and Pricing

With schools and colleges back in session, you can only hope patients start coming in for their influenza vaccine, so communities can keep the spread of seasonal flu to a minimum this year. Healthcare providers should prepare for the flux of injections by updating their billing systems with the 2019 Average Sales Price (ASP) Drug Pricing files and reading the latest vaccine recommendations.

Vaccine codes and payment allowances for the 2019-2020 season are shown in Table A. These payment allowances are effective Aug. 1, 2019, through July 31, 2020. Download the 2019 Average Sales Price (ASP) Drug Pricing Files for up-to-date pricing information on all Medicare Part B drugs.

Table A: Payment Allowances and Effective Dates for the 2019-2020 Flu Season

Code Descriptor Labeler Name Drug Name Payment Allowance
90653 Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use Seqirus Fluad $59.530
90662 Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use Sanofi Pasteur Fluzone High-Dose) $56.006
90672 Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use MedImmune FluMist Quadrivalent $26.876
90674 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use Seqirus Flucelvax Quadrivalent (Pres Free) $28.130
90682 Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use Sanofi Pasteur Flublok Quadrivalent $56.006
90685 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use Sanofi Pasteur

Seqirus

Fluzone Quadrivalent 0.25ml (Pres Free)
Afluria Quadrivalent 0.25 ml (Pres Free)
$20.343
90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use GlaxoSmithKline

Sanofi Pasteur

Seqirus

Fluarix Quadrivalent (Pres free)
Flulaval Quadrivalent (Pres Free)
Fluzone Quadrivalent (Pres Free)
Afluria Quadrivalent (2019/2020) (Pres Free)
$19.032
90687 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use Sanofi Pasteur

Seqirus

Fluzone Quadrivalent  0.25ml
Afluria Quadrivalent 0.25ml
$9.403
90688 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use GlaxoSmithKline

Sanofi Pasteur

Seqirus

Flulaval Quadrivalent
Fluzone Quadrivalent
Afluria Quadrivalent
$17.835
90756 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use Seqirus Flucelvax Quadrivalent $26.657

Source: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/VaccinesPricing.html

 

The Medicare Part B payment allowance limits for seasonal influenza and pneumococcal vaccines are 95% of the Average Wholesale Price (AWP) as reflected in the published compendia except where the vaccine is furnished in a hospital outpatient department. When the vaccine is furnished in the hospital outpatient department, payment for the vaccine is based on reasonable cost.

Novitas Solutions, Medicare Administrative Contractor for Jurisdiction H and L, has published administration fees for the following three HCPCS Level II codes on its website. (Check your MAC’s website for applicable administrative fees.)

G0008 – Administration of Influenza Virus Vaccine
G0009 – Administration of Pneumococcal Vaccine
G0010 – Administration of Hepatitis B Vaccine

Annual Part B deductible and coinsurance amounts do not apply for the influenza virus and the pneumococcal vaccinations. All physicians, non-physician practitioners, and suppliers who administer these vaccinations must take assignment on the claim for the vaccine, according to the Centers for Medicare & Medicaid Services (CMS).

Read “How to Code Flu – from Prevention to Care” for guidance on how to code flu shots.

Primary Changes and Updates in CDC Recommendations

“Routine annual influenza vaccination of all persons aged ≥6 months who do not have contraindications continues to be recommended,” per the Centers for Disease Control and Prevention (CDC). The American Academy of Pediatrics (AAP) says it will no longer express a preference for the flu shot over nasal spray vaccine for children during the 2019-2020 flu season, and is recommending using the flu shot (inactivated influenza vaccine, IIV) as the primary vaccine choice.

Read AAP’s full statement regarding the flu vaccine for 2019-2020.

Be aware of two recent regulatory actions:

  • In October 2018, FDA approved an expanded age indication for Afluria Quadrivalent (IIV4). Previously licensed for persons aged ≥5 years, Afluria Quadrivalent (IIV4) is now licensed for persons aged ≥6 months. The dose volume is 0.25 mL per dose (containing 7.5 µg of hemagglutinin (HA) per vaccine virus) for children aged 6 through 35 months and 0.5 mL per dose (containing 15 µg of HA per vaccine virus) for all persons aged ≥36 months (≥3 years).
  • In January 2019, FDA approved a change in dose volume for Fluzone Quadrivalent (IIV4). Previously, the dose volume for children aged 6 through 35 months was 0.25 mL (containing 7.5 µg of HA per vaccine virus). Children aged 6 through 35 months who receive Fluzone Quadrivalent may now receive either 0.25 mL (containing 7.5 µg of HA per vaccine virus) or 0.5 mL (containing 15 µg of HA per vaccine virus) per dose. Children aged ≥36 months (≥3 years) and adults should receive 0.5 mL per dose.
  • Get more information regarding CDC recommendations.

What’s Going Around This Year?

The CDC reports the 2019–20 U.S. trivalent influenza vaccines will contain:

  • an A/Brisbane/02/2018 (H1N1)pdm09–like virus,
  • an A/Kansas/14/2017 (H3N2)–like virus, and
  • a B/Colorado/06/2017–like virus (Victoria lineage).

The 2019–20 U.S. quadrivalent influenza vaccines will contain HA derived from these three viruses and an additional influenza B virus HA, a B/Phuket/3073/2013–like virus (Yamagata lineage). Compared with the 2018–19 season, the composition for 2019–20 represents updates in the influenza A(H1N1)pdm09 and influenza A(H3N2) components of the vaccine.


Source:

CPB : Online Medical Billing Course

Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season. MMWR Recomm Rep 2019;68(No. RR-3):1–21. DOI: http://dx.doi.org/10.15585/mmwr.rr6803a1

Renee Dustman
Follow me

Renee Dustman

Executive Editor at AAPC
Renee Dustman, BS, AAPC MACRA Proficient, is an executive editor at AAPC. She holds a Bachelor of Science degree in Media Communications - Journalism. Renee has more than 20 years experience in print production and content management. Follow her on Twitter @dustman_aapc.
Renee Dustman
Follow me

Latest posts by Renee Dustman (see all)

About Has 707 Posts

Renee Dustman, BS, AAPC MACRA Proficient, is an executive editor at AAPC. She holds a Bachelor of Science degree in Media Communications - Journalism. Renee has more than 20 years experience in print production and content management. Follow her on Twitter @dustman_aapc.

Leave a Reply

Your email address will not be published. Required fields are marked *

Sponsored Ads